The estimated Net Worth of Advisors Llc Orbi Med Genes... is at least $22.1 Million dollars as of 15 August 2023. Advisors Genes owns over 822,680 units of Galecto stock worth over $19,816,120 and over the last 2 years Advisors sold GLTO stock worth over $2,298,261.
Sign up
Advisors Genes GLTO stock SEC Form 4 insiders trading
Advisors has made over 7 trades of the Galecto stock since 2023, according to the Form 4 filled with the SEC. Most recently Advisors sold 822,680 units of GLTO stock worth $617,010 on 15 August 2023.
The largest trade Advisors's ever made was selling 822,680 units of Galecto stock on 15 August 2023 worth over $617,010. On average, Advisors trades about 214,947 units every 19 days since 2023. As of 15 August 2023 Advisors still owns at least 1,510,375 units of Galecto stock.
You can see the complete history of Advisors Genes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Galecto
Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong und Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.
What does Galecto do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
What does Galecto's logo look like?
Complete history of Advisors Genes stock trades at Galecto
Galecto executives and stock owners
Galecto executives and other stock owners filed with the SEC include:
-
Dr. Hans T. Schambye,
Co-Founder, Pres, CEO & Director -
Prof. Bertil Lindmark M.D., Ph.D.,
Chief Medical Officer -
Anders Pedersen,
Chief Operating Officer -
Dr. Stephanie Oestreich Ph.D.,
Chief Bus. Officer -
Garrett Winslow,
Sr. VP & Gen. Counsel -
Jonathan P. Freve CPA, CPA,
Chief Financial Officer -
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
Co-Founder & Member of the Clinical Advisory Board - IPF -
Dr. Hakon Leffler,
Co-Founder -
Ulf J. Nilsson,
Co-Founder -
Advisors Llc Orbi Med Genes...,
-
Holdings A/S Novo,
10% owner -
Carl Goldfischer,
-
Anders Pedersen,
Chief Operating Officer -
Hans T. Schambye,
Chief Executive Officer -
Stephan Christgau,
Director -
Advisors Llc Orbi Med Advis...,
-
Bertil Lindmark,
Chief Medical Officer -
Jonathan Freve,
Chief Financial Officer -
Chau Quang Khuong,
Director -
Stephanie Oestreich,
Chief Business Officer -
Jayson Donald Alexander Dallas,
-
Amit Munshi,
-
Anne Prener,
-
David Shapiro,
-
Garrett Winslow,
General Counsel